vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and LIGHTPATH TECHNOLOGIES INC (LPTH). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $16.4M, roughly 1.2× LIGHTPATH TECHNOLOGIES INC). LIGHTPATH TECHNOLOGIES INC runs the higher net margin — -57.5% vs -177.4%, a 119.9% gap on every dollar of revenue. On growth, LIGHTPATH TECHNOLOGIES INC posted the faster year-over-year revenue change (120.2% vs -11.5%). LIGHTPATH TECHNOLOGIES INC produced more free cash flow last quarter ($2.0M vs $-23.1M). Over the past eight quarters, LIGHTPATH TECHNOLOGIES INC's revenue compounded faster (45.7% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

LightPath Technologies Inc designs, manufactures and distributes high-precision optical components and assemblies, including aspheric lenses, infrared optics, and fiber optic products. It serves global clients across industrial automation, aerospace, defense, medical imaging, and telecommunications sectors.

LAB vs LPTH — Head-to-Head

Bigger by revenue
LAB
LAB
1.2× larger
LAB
$19.6M
$16.4M
LPTH
Growing faster (revenue YoY)
LPTH
LPTH
+131.7% gap
LPTH
120.2%
-11.5%
LAB
Higher net margin
LPTH
LPTH
119.9% more per $
LPTH
-57.5%
-177.4%
LAB
More free cash flow
LPTH
LPTH
$25.0M more FCF
LPTH
$2.0M
$-23.1M
LAB
Faster 2-yr revenue CAGR
LPTH
LPTH
Annualised
LPTH
45.7%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q2 FY2026

Metric
LAB
LAB
LPTH
LPTH
Revenue
$19.6M
$16.4M
Net Profit
$-34.7M
$-9.4M
Gross Margin
48.5%
36.8%
Operating Margin
-168.5%
-52.6%
Net Margin
-177.4%
-57.5%
Revenue YoY
-11.5%
120.2%
Net Profit YoY
-28.8%
-260.1%
EPS (diluted)
$-0.09
$-0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
LPTH
LPTH
Q4 25
$16.4M
Q3 25
$19.6M
$15.1M
Q2 25
$21.8M
$12.2M
Q1 25
$40.8M
$9.2M
Q4 24
$7.4M
Q3 24
$22.1M
$8.4M
Q2 24
$22.5M
$8.6M
Q1 24
$45.5M
$7.7M
Net Profit
LAB
LAB
LPTH
LPTH
Q4 25
$-9.4M
Q3 25
$-34.7M
$-2.9M
Q2 25
$-33.5M
$-7.1M
Q1 25
$-26.0M
$-3.6M
Q4 24
$-2.6M
Q3 24
$-26.9M
$-1.6M
Q2 24
$-45.7M
$-2.4M
Q1 24
$-32.2M
$-2.6M
Gross Margin
LAB
LAB
LPTH
LPTH
Q4 25
36.8%
Q3 25
48.5%
29.8%
Q2 25
48.8%
22.0%
Q1 25
48.4%
29.1%
Q4 24
26.0%
Q3 24
54.9%
33.9%
Q2 24
46.1%
29.2%
Q1 24
53.1%
20.9%
Operating Margin
LAB
LAB
LPTH
LPTH
Q4 25
-52.6%
Q3 25
-168.5%
-16.6%
Q2 25
-118.1%
-38.0%
Q1 25
-80.8%
-36.3%
Q4 24
-33.5%
Q3 24
-120.9%
-16.4%
Q2 24
-134.5%
-25.6%
Q1 24
-132.2%
-33.6%
Net Margin
LAB
LAB
LPTH
LPTH
Q4 25
-57.5%
Q3 25
-177.4%
-19.2%
Q2 25
-153.7%
-57.8%
Q1 25
-63.8%
-39.1%
Q4 24
-35.2%
Q3 24
-122.0%
-19.3%
Q2 24
-203.3%
-27.3%
Q1 24
-70.6%
-33.7%
EPS (diluted)
LAB
LAB
LPTH
LPTH
Q4 25
$-0.20
Q3 25
$-0.09
$-0.07
Q2 25
$-0.09
$0.19
Q1 25
$-0.07
$-0.44
Q4 24
$-0.07
Q3 24
$-0.07
$-0.04
Q2 24
$-0.12
$-0.15
Q1 24
$-0.27
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
LPTH
LPTH
Cash + ST InvestmentsLiquidity on hand
$129.4M
$73.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$77.9M
Total Assets
$539.6M
$148.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
LPTH
LPTH
Q4 25
$73.6M
Q3 25
$129.4M
Q2 25
$158.6M
$4.9M
Q1 25
$150.9M
Q4 24
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Total Debt
LAB
LAB
LPTH
LPTH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
$535.0K
Q1 24
$55.0M
$599.4K
Stockholders' Equity
LAB
LAB
LPTH
LPTH
Q4 25
$77.9M
Q3 25
$399.7M
$21.4M
Q2 25
$424.5M
$15.6M
Q1 25
$454.6M
$15.7M
Q4 24
$26.7M
Q3 24
$489.3M
$29.4M
Q2 24
$510.3M
$30.2M
Q1 24
$577.3M
$31.7M
Total Assets
LAB
LAB
LPTH
LPTH
Q4 25
$148.6M
Q3 25
$539.6M
$87.3M
Q2 25
$557.0M
$81.5M
Q1 25
$579.6M
$81.4M
Q4 24
$45.8M
Q3 24
$681.5M
$48.4M
Q2 24
$708.7M
$48.1M
Q1 24
$777.7M
$49.7M
Debt / Equity
LAB
LAB
LPTH
LPTH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
0.02×
Q1 24
0.10×
0.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
LPTH
LPTH
Operating Cash FlowLast quarter
$-22.2M
$2.8M
Free Cash FlowOCF − Capex
$-23.1M
$2.0M
FCF MarginFCF / Revenue
-118.1%
12.0%
Capex IntensityCapex / Revenue
4.5%
5.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$-6.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
LPTH
LPTH
Q4 25
$2.8M
Q3 25
$-22.2M
$-1.1M
Q2 25
$-20.7M
$-2.6M
Q1 25
$-30.3M
$-3.2M
Q4 24
$-737.4K
Q3 24
$-27.9M
$-1.7M
Q2 24
$-39.0M
$64.7K
Q1 24
$-62.5M
$-394.2K
Free Cash Flow
LAB
LAB
LPTH
LPTH
Q4 25
$2.0M
Q3 25
$-23.1M
$-1.2M
Q2 25
$-22.6M
$-3.3M
Q1 25
$-35.3M
$-3.7M
Q4 24
$-817.8K
Q3 24
$-30.1M
$-1.8M
Q2 24
$-41.0M
$-225.5K
Q1 24
$-63.3M
$-802.5K
FCF Margin
LAB
LAB
LPTH
LPTH
Q4 25
12.0%
Q3 25
-118.1%
-8.1%
Q2 25
-103.6%
-27.3%
Q1 25
-86.6%
-40.0%
Q4 24
-11.0%
Q3 24
-136.4%
-21.2%
Q2 24
-182.2%
-2.6%
Q1 24
-138.9%
-10.4%
Capex Intensity
LAB
LAB
LPTH
LPTH
Q4 25
5.3%
Q3 25
4.5%
0.5%
Q2 25
8.7%
5.6%
Q1 25
12.4%
4.6%
Q4 24
1.1%
Q3 24
10.2%
0.9%
Q2 24
8.6%
3.4%
Q1 24
1.7%
5.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

LPTH
LPTH

Other$7.9M48%
Infrared Components$5.0M31%
Visible Components$3.4M21%

Related Comparisons